by telrheum | Jun 19, 2024 | Psoriatic Arthritis, Spondyloarthritis
Background/Purpose: The study explores the differences between males and females with axial juvenile spondyloarthritis (axJSpA), a type of juvenile inflammatory arthritis. The goal was to understand if there are distinct clinical and imaging features based on sex....
by telrheum | Jun 19, 2024 | Juvenile Idiopathic Arthritis, Rheumatic Drugs, tumour necrosis factor inhibitors (TNFis)
Background: Juvenile idiopathic arthritis (JIA) is a condition in children causing joint inflammation. Etanercept is a common medication for JIA, but the best dose for effectiveness is unclear. This study looks at whether increasing the dose of etanercept helps...
by telrheum | Jun 16, 2024 | Biologic Therapy, JAK Inhibitor, systemic juvenile idiopathic arthritis
Background: Systemic juvenile idiopathic arthritis (sJIA) is a severe form of arthritis in children that can lead to serious complications like macrophage activation syndrome (MAS) and lung disease. Even with current treatments like steroids and IL-1 inhibitors, some...
by telrheum | Jun 16, 2024 | Degenerative Arthritis, Arthritis Supplements, Dietary Changes, Osteoarthritis
Background: The “Plants for Joints” (PFJ) program is a 16-week lifestyle intervention aimed at people with osteoarthritis (OA) of the hip or knee and metabolic syndrome. The program includes a whole-food, plant-based diet, physical activity, and stress management....
by telrheum | Jun 15, 2024 | Osteoarthritis, Antibody Therapy, Gene Therapy
Background: This study aimed to evaluate the safety and effectiveness of XT-150, a new gene therapy, for treating moderate to severe pain caused by osteoarthritis (OA) of the knee. XT-150 is designed to produce a special version of the anti-inflammatory protein...
